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Abstract.  The vitronectin receptor (ot~B3) is a member 
of the integrin superfamily of adhesive protein recep- 
tors that mediate a wide spectrum of adhesive cellular 
interactions,  including attachment to vitronectin, yon 
WiUebrand factor, fibrinogen, and thrombospondin. 
We have studied the binding of fibronectin to the 
purified vitronectin receptor, and the role of this 
receptor in the attachment of cells to fibronectin.  A 
solid-phase microtiter assay was developed to inves- 
tigate the binding properties of the vitronectin recep- 
tor.  Purified tx433 bound fibronectin with high affinity 
in a  saturable,  divalent cation-dependent manner. 
Binding was inhibited by soluble vitronectin,  by 
RGD-containing peptides, and by LM609, a monoclo- 
nal antibody against the vitronectin receptor known to 
inhibit the binding of adhesive proteins to Otvfl3. Im- 
munoinhibition  experiments  showed that M21  human 
melanoma cells, which express the fibronectin recep- 
tor, aSfll,  as well as art3,  used both of these integrins 
to attach and spread on fibronectin.  In support of this 
finding,  M21-L cells, a variant cell line that spe- 
cifically lacks tXvfl3 but expresses otv/31, attached and 
spread poorly on fibronectin. In addition,  otv~ from 
surface-labeled M21 cells was retained,  and selec- 
tively eluted by RGDS from a fibronectin affinity 
column.  These results indicate that o~B3 acts in con- 
cert with ot5/3~ in promoting fibronectin recognition by 
these cells.  We conclude that fibronectin binds to the 
otvfl3 vitronectin receptor specifically and with high 
affinity, and that this interaction is biologically rele- 
vant in supporting cell adhesion to matrix proteins. 
T  I-IE vitronectin receptor (oLvB3) is a member of a su- 
perfamily of receptors known as the integrins (Hynes, 
1987),  which mediate a broad spectrum of cell-cell 
and cell-substrate interactions.  It is now appreciated that 
such apparently diverse phenomenon as platelet aggregation 
(Phillips  et al.,  1980),  endothelial  cell adhesion  to matrix 
proteins (Charo et al., 1987; Cheresh,  1987), embryogene- 
sis (Duband et al., 1988), and perhaps tumor cell metastasis 
(Humphries et al., 1986) are mediated by structurally and/or 
immunologically related integrin receptors expressed on the 
cell surface. 
Integrins  are heterodimer complexes of noncovalently as- 
sociated or- and/5-subunits.  The integrin superfamily  can be 
divided into subfamilies based on the presence of at least five 
homologous/~-subunits  that can associate with one or more 
ot-subunits. The spectrum of ligands bound to each receptor 
is dictated by the specific o~- and/3-subunit pairing of the bet- 
erodimer complex. For example,  cts/3~ shows a very specific 
ligand  recognition  capability and appears to bind only fi- 
bronectin, whereas endothelial  cell otzOl is a more promis- 
cuous receptor and binds both laminin  and collagen (Elites 
and Hemler, 1989; Kirchhofer  et al.,  1990). In addition,  a 
given cell may express two or more integrins  that bind the 
same adhesive proteins.  The ligand binding specificity of the 
vitronectin  receptor has been unclear. 
Pytela et al.  (1986)  found that  the vitronectin  receptor 
reconstituted into phospholipid vesicles composed of phos- 
phatidyl choline bound to vitronectin-,  but not fibronectin-, 
fibrinogen-, or thrombospondin-coated  surfaces. Subsequent 
studies  found that two different monoclonal antibodies that 
react with ot,/33 blocked the adhesion  of human umbilical 
vein endothelial  cells to yon W'dlebrand  factor (vWf)  1 and 
fibrinogen,  suggesting that otvB3 interacted with these adhe- 
sive proteins as well. Neither of these antibodies blocked the 
adhesion  of endothelial  cells, which express both otv/33 and 
cts#~, to fibronectin  (Charo et al.,  1987; Cheresh,  1987). 
Recently,  Conforti et al.  (1990)  found that  otv~3 reconsti- 
tuted into phosphatidyl choline vesicles bound only vitro- 
nectin, in agreement with the earlier work of Pytela, and that 
when a mixture of  phosphatidyl serine and phosphatidyl cho- 
line was used to form the vesicles o~,B3 also bound vWf and 
fibronectin.  It was not determined, however, whether ot,B3 
in intact cells bound these adhesive proteins,  or if this bind- 
ing was involved in adhesive  cellular interactions. 
In this  paper we present evidence  that  purified  cx;B3 is 
capable of recognizing  fibronectin  in a specific and RGD- 
dependent manner,  and that it and the fibronectin  receptor, 
o~sB~,  act  in  concert  in  mediating  the  attachment  and 
1. Abbreviation  used in this paper:  vWf, yon Willebrand factor. 
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strate.  These data  provide evidence for a novel biological 
role  for  the  vitronectin  receptor,  o~f13, in  mediating  the 
adhesion of cells to fibronectin in the extraceUular  matrix. 
Materials and Methods 
Purification of Proteins 
The vitronectin receptor (av~3) was purified from human placenta as de- 
scribed (Smith and Cheresh,  1988).  Briefly,  one  or  two  fresh human 
placentas were homogenized in a food processor in the presence of 20 mM 
Tris-HCl, 150 mM NaCI, 2.0 mM CaCI2, 100 mM octyl-glucopyranoside, 
0.05% NAN3, pH 7.5. The homogenates were centrifuged  at 100 g to re- 
move the tissue,  and again at 10,000 g. The supernat~ts were then passed 
over an LM609 affinity column to selectively retain the av/33 complex,  and 
eluted with 10 mM acetate, 150 mM NaC1, 0.1% NP-40, 2 mM CaC12, pH 
2.5. The eluted material was further purified by chromatography on a wheat 
germ affinity column (Sigma Chemical Co., St. Louis, MO). We obtained 
'~1 mg of highly purified c~#3 from each placenta. This material was ho- 
mogeneous  on overloaded  SDS-polyacrylamide  gels,  and did not contain 
detectable levels of platelet GPIIb-llla when assayed by ELISA. 
Human vitronectin was purified from plasma as described (Yatohga et 
al., 1988). Briefly, human plasma was clotted in a glass beaker in the pres- 
ence of proteas¢ inhibitors, and applied to a beparin-Sepharose column in 
the presence of 8 M urea. Purified vitronectin was eluted with 10 mM Na- 
phosphate buffer (pH 7.7) containing EDTA (5 mM), urea (8 M), and NaCI 
(0.5 M). Human plasma fibronecfin was purified by gelatin-agarose  affinity 
chromatography as described (Engvall et al.,  1978).  Further purification 
was  performed by gel-filtration  on a  Sephacryl-S-300 (Pharmacia Fine 
Chemicals, Piscataway, NJ) column equilibrated in 50 mM Tris-HC1,  100 
mM NaC1, pH 7.4. Peak fractions were analyzed on reduced SDS-gels, and 
were free of  detectable fibrinogen. Human fibrinogen  and vWf  were purified 
as described (Cberesh et al.,  1989). 
Antibodies 
The c~v~3 monoclonal LM609 was produced as described (Cheresh and 
Spiro,  1987). The fibronectin receptor antibody BIIG2 (Werb et al., 1989) 
was provided by Dr. Caroline Damsky (University of California,  San Fran- 
cisco,  CA) and the GPIIb-IIIa monoclonal 10E5 (Coller et al.,  1983) was 
provided by Dr.  Barry Coller (State University of New  York at Stony 
Brook, NY). 
Biotinylation of  Adhesive Proteins 
For biotinylation, proteins were  dialyzed  into 0.1  M  NaHCO3,  0.1  M 
NaCI, pH 8.2 and centrifuged in a table top ultracentrifuge (model TL-100; 
Beckman Instruments, Inc., Palo Alto, CA) at 100,000 g for 30 min at 4°C 
to remove any particulate matter, and the protein concentration was adjusted 
to a concentration  of 1 mg/rnl. Sulfo-NHS-Biotln  (No. 21217; Pierce Chem- 
ical Co., Rockford, IL) was added as a solid (0.2 mg of biotin ester/ml adhe- 
sive protein)rand gently mixed on an end-over-end Nutator (Clay Adams, 
Parsippany, NJ) for 30 rain at room temperature.  Unreacted biotin ester was 
removed by exhaustive  dialysis against 50 mM Tris-HCI,  100 mM NaCI, 
0.05%  NAN3, pH 7.4,  at 4°C,  and the biotinylated protein was stored at 
4°C until used. 
Binding Assay 
The binding of adhesive proteins to  immobilized ~v{/3 was  performed 
using a modification of the method recently described for platelet GPIIb-IIIa 
(Steiner,  B., and P.  Hadvary.  1988. C/rc.  Suppl. 78[Pt.  2]:2478[Abstr.]; 
Charo et al.,  1990). The vitronectin receptor (1 mg/ml) was diluted 1:200 
with a  Triton X-100-free buffer containing 20 mM Tris-HCl,  150 mM 
NaCI, 1 mM CaCI2, 0.02% NAN3, and then immediately added to 96-well 
microtiter plates (Linbro E.I.A. H Plus Microtitration plate; Flow Labora- 
tories, Inc., McLean, VA) at 0.1 ml (0.5/~g) per well, and incubated over- 
night at 4°C.  Microfiter plates were stored at 4°C for up to 2 mo before 
being used. At the time of the experiment, the wells were washed once with 
50 mM Tris,  100 mM NaC1, 2 mM CaC12, 0.02% NAN3, 1 mg/ml BSA, 
pH 7.4 (binding buffer) and then incubated in 0.1 ml of a solution of binding 
buffer with 35 mg/ml BSA for 2 h at 30°C to block nonspecific  binding, 
followed by an additional wash with binding buffer (with 1 mg/ml BSA). 
Biotinylated adhesive proteins (0.1 mi/well) were added and incubated for 
3 h at 30°C in binding buffer (with 1 mg/ml BSA). After the incubation the 
wells were aspirated completely and washed once with 250/zl of binding 
buffer. Bound ligand was quantitated by the addition of 0.1 ml of an antibio- 
tin antibody conjugated to alkaline phosphatase (1:2,000 dilution; Sigma 
Chemical Co.), followed by a wash with binding buffer and the addition of 
100 ~1 of the substrate, p-nitrophenyl phosphate, prepared daily according 
to the manufacturer's instructions (Biorad Alkaline Phosphate Substrate 
Kit; Bio-Rad Laboratories, Richmond, CA). The kinetics of  the color devel- 
opment were followed using a microtiter plate reader (Molecular Devices, 
Menlo Park,  CA).  All reaction rates were determined within the linear 
range,  and all data points represent the mean of quadruplicate  determina- 
tions. Standard deviations of these quadruplicates were <20%, and often 
<10% of the mean. Nonspecific binding was measured in every experiment 
by determining the binding of biotinylated ligands to BSA-coated wells, and 
also by determining the binding in the presence of RGDS (250/zM) or 
EDTA (5 mM), and was consistently <10%. 
Binding of  c~,~3 to Immobilized Fibronectin 
Human fibronectin  was digested with chymotrypsin (enzyme/substrate ratio 
of 1:20) to produce the 120-kD cell-binding  domain fragment, as described 
(Pytela et al.,  1985a),  which was coupled  to cyanogen bromide activated 
Sepharos¢  (Pharmacia Fine Chemicals). M21  cells were surface labeled 
using lactoperoxidase-catalyzed  iodiuation (Charo et al., 1986), and lysed 
with 200 mM n-octyl a-D-glucopyranoside  (n-octyl ~-glucoside) in 25 mM 
TBS. The cell lysate was slowly passed (at room temperature) over the 120- 
kD affinity column equilibrated in TBS (pH 7.4) with 50 mM octylglucoside 
and 2 mM MgC12. It was then washed  with the same buffer, and eluted 
with RGES (1 mg/ml) and then RGDS (1 mg/ml), as described by Pytela 
et al. (1985a). Each fraction (0.5 ml) was immunoprecipitated with LM609 
(20/~g/ml) and run on reduced 7.5 % SDS-polyacrylamide gels, which were 
then examined by autoradiography. 
Cell Adhesion 
M21 and M21-L cells (Cheresh and Spiro,  1987) were grown in RPMI sup- 
plemented with 20% (vol/vol) FCS and antibiotics. The cells were partially 
depleted of methionine by incubation for 2-4 h in RPMI plus PBS-dialyzed 
serum, and then labeled by incubation with 250/~Ci of [35S]methionine 
overnight.  The cells were then washed three times with serum-free media, 
harvested, and added to vitronectin-coated microtiter wells.  After 30-60 
rain at 37°C (in the presence or absence of antibodies) the cells were washed 
three times and solubilized  (0.1 M  NaOH,  60 rain, room temperature). 
Bound cells were quantitated by counting beta emissions.  In the control 
wells ,~50% of the added cells attached to the adhesive protein. Adhesion 
of cells to BSA-coated wells was <5 % of the adhesion to vitronectin. All 
measurements were performed in triplicate (or quadruplicate), and the stan- 
dard deviations were  10% of the mean or less. 
Results 
Ligand Binding to the Purified Vitronectin 
Receptor (a,B~) 
To investigate the ligand binding properties of avO3 a solid- 
phase microtiter assay was developed. In this assay purified 
c~J~3 was immobilized on the bottoms of microtiter wells, 
and biotinylated adhesive protein ligands were added and in- 
cubated with the receptor. As seen in Fig. 1, there was high 
affinity,  saturable  binding of vitronectin, fibronectin, vWf, 
and fibrinogen to the purified vitronectin receptor. In con- 
trast,  there was little or no binding of laminin or BSA to 
The binding of biotinylated adhesive proteins to av~3 was 
specific.  Fibronectin and vitronectin binding to avfl3 was 
blocked by a monoclonal antibody (LM609) known to in- 
hibit the binding of cells to vitronectin (Cheresh and Spiro, 
1987), but not by monoclonals to the fibronectin receptor 
(BIIG2) or to the platelet GPHb-HIa complex 00E5) (Fig. 
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Figure I. Binding of adhesive proteins to the purified vitronectin 
receptor (~v~3). Biotinylated adhesive proteins were added at the 
indicated concentrations to microtiter wells coated with purified 
c~d53, and incubated for 3 h at 30°C. After unbound ligand was re- 
moved by washing, the bound adhesive protein was determined by 
ELISA. Data points shown are the mean of quadruplicate determi- 
nations. 
2). As expected for a member of the integrin superfamily of 
receptors, chelation of  divalent cations with EDTA also com- 
pletely blocked binding. In addition, binding was blocked by 
the tetrapeptide RGDS, but not by RGES (not shown). The 
dodecapeptide from the gamma chain of fibrinogen (amino 
acids 400-411) did not block fibronectin or vitronectin bind- 
ing to O~v/~3, although it is known to block the binding of ad- 
hesive proteins to GPII'b-HIa on activated platelets (Kloc- 
zewiak et al.,  1984). The binding of vWf and fibrinogen to 
otv/~3 was examined with the same antibodies and peptides, 
and the results were exactly as found for fibronectin and vi- 
tronectin (data not shown).  Thus,  immobilized O/v/~3  binds 
adhesive proteins with the properties expected of the cellular 
vitronectin receptor. 
The binding of vitronectin and  fibronectin to otd33 was 
mutually exclusive. Fibronectin blocked the binding of bio- 
tinylated vitronectin (15 nM) to otd33, and half-maximal in- 
hibition was achieved at a  fibronectin concentration of 25 
nM,  which was comparable to the concentration of vitro- 
nectin required to inhibit this binding (Fig.  3).  Similarly, 
vitronectin very effectively blocked the binding of fibronec- 
tin  to  av/~3 (data  not  shown).  These results  indicate that 
fibronectin and vitronectin compete when binding to ad~3, 
and  suggest that  vitronectin binds  with  somewhat higher 
affinity. 
Additional  evidence  for  a  specific  interaction  between 
c<d33 and fibronectin was obtained by passing the lysate of 
surface-labeled M21  melanoma cells,  which express both 
the vitronectin receptor (a~/33) and the fibronectin receptor 
(ot5/3~) (Cheresh  et  al.,  1989)  over  a  fibronectin affinity 
column, as described by Pytela et al. (1985b). The vitronec- 
tin receptor was retained on this column, and was eluted by 
RGDS, but not by RGES (Fig. 4). 
The VRronectin Receptor Is Involved in the Adhesion 
of  Melanoma Cells to Fibronectin 
To  determine  whether  the  binding  of fibronectin  to  the 
vitronectin receptor was functionally significant in the con- 
text of a  cell membrane we examined the adhesion of two 
related melanoma cell lines to fibronectin-coated surfaces. 
M21  cells attached and  spread well on fibronectin-coated 
slides (Fig.  5).  M21  cell adhesion to fibronectin was  not 
significantly inhibited by antibodies against the fibronectin 
receptor (BIlG2) or the vitronectin receptor (LM609), but 
was blocked by the combination of the two antibodies. This 
suggested that o~,,~3 and ,v5/~1 were both involved in M21 cell 
adhesion to fibronectin. To further investigate the role of 
~v/~3 in cellular attachment to fibronectin expe  "nments were 
performed with M21-L cells, which is a mutant cell line that 
specifically lacks otd~3, but expresses normal levels of the 
Figure 2.  Binding of fibronectin and vitronectin to immobilized 
ot,#s. Biotinylated fibroneetin (10 riM) or vitronectin (10 riM) was 
added to miemtiter wells coated with ~v/~3 in the presence or ab- 
sence of RGDS (100/am), the t~v/33 monoclonal antibody LM609 
(10/~g/ml), EDTA (5 raM), the txs/3~ fibroneetin receptor antibody 
BIIG2 (10/~g/ml), the GPIlb-llla monoclonal antibody 10E5 (10 
pg/ml), and the dodeeapeptide (7400-411) from the gamma chain 
of fibrinogen (200/~M), and incubated for 3 h at 30°C. Binding is 
expressed as percent of control. Error bars represent the standard 
deviation of quadruplicate determinations. 
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Rgure 3. Fibronectin blocks the binding of vitronectin to ~vB3. Bio- 
tinylated vitronectin (15 riM) was added to microtiter wells coated 
with  c~./~3 in  the  presence  of the  indicated  concentrations  of 
fibrone~tin or vitroneetin. Vitronectin that bound to ct,/33 was de- 
termined by ELISA, as described in Fig.  1. 
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Antibody or peptide  M21 cells  M21-L cells 
cpm  cpm 
Control  405,997  101,338 
BIIG2  324,932  37,323 
LM609  325,026  132,608 
BIIG2  +  LM609  106,612  51,492 
GRGDSPK  62,704  33,205 
RGES  365,283  109,925 
Adhesion of metabolically  labeled M21 and M21-L melanoma cells to fibro- 
nectin was measured in the presence or absence of antibodies  to the cq~ fi- 
bronectin receptor (BIIG2; 20 #g/ml), the ave3 vitronectin receptor (LM609; 
20/~g/ml),  and peptides GRGDSPK and RGES (300 pM). Very similar results 
were obtained when each antibody was used at 10/~g/ml.  Data is from one of 
three similar experiments. 
Figure 4.  Binding of c~v/33 to immobilized fibronectin. Surface- 
labeled M21 cells were lysed and passed over a l-m1 column of the 
120-kD cell binding domain of fibronectin coupled to Sepharose. 
After extensive washing  the column was eluted with RGES followed 
by RGDS. Shown  is an SDS gel of  the eluted fractions (1 ml) immu- 
noprecipitated with LM609. Lame  1, total lysate. The RGES elution 
was begun at column fraction number 8, and gel lanes 2-4 represent 
column fractions 10-12. The RGDS elution was begun at column 
fraction number 13, and gel lanes 5-10 represent column fractions 
15-20. 
fibronectin receptor (Cheresh and Spiro,  1987;  Cheresh et 
al.,  1989).  As  shown  in  Fig.  5,  these  cells  attached  to 
fibronectin, but were poorly spread.  Adhesion of M21-L 
cells to fibronectin was completely blocked by BIIG2, and 
as expected, was unaffected by LM609.  These results are 
quantitated in Table I, and indicate that av/5~ acts in concert 
with c~5/3~ in promoting M21 cell attachment and spreading 
on fibronectin. 
Discussion 
In this study we present biochemical and functional evidence 
that the vitronectin receptor c~vB3, mediates cellular interac- 
tions with fibronectin. Using a  sensitive and reproducible 
solid-phase assay we have found specific and high affinity 
binding of vitronectin, vWf, fibrinogen, and fibronectin to 
the purified vitronectin receptor. We have further found that 
av/53 mediated  the  adherence  and  spreading  of a  human 
melanoma  cell line to  fibronectin and bound  specifically 
to a  fibronectin affinity column.  We conclude from these 
studies that c~vfl3  is a multifunctional receptor that binds at 
least  four  RGD-containing  adhesive  proteins,  including 
fibronectin. 
Figure 5. Adhesion of melanoma cells to fibronectin. M21 and M21-L melanoma cells were added to fibronectin-coated microtiter wells 
in the presence or absence of the vitronectin receptor antibody LM609 (20 ~g/ml) or the fibronectin receptor antibody BIIG2 (20/~g/ml). 
Shown are phase-contrast photomicrographs taken with a 10×  objective. 
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simple and rapid method for studying the binding properties 
of integrins. We have recently used a similar solid-phase as- 
say to identify a peptide derived from GPBIa that inhibits the 
binding  of fibrinogen  to  the  platelet  GPllb-ma  complex 
(Charo et al.,  1990). In using this assay we have found that 
vitronectin,  vWf,  fibrinogen,  and fibronectin bind to otvB3 
in a similar manner.  The binding of these adhesive proteins 
to purified cx,B3 was divalent cation dependent, and was in- 
hibited by RGD peptides and a monoclonal antibody known 
to  inhibit  vitronectin  binding  to  C~vB3 on  whole cells.  In 
contrast,  ligand  binding  to  ¢xvB3 was  not  blocked by the 
dodecapeptide from the gamma chain of fibrinogen (at con- 
centrations up to 500 #M), which is consistent with recent 
reports that the dodecapeptide interacts  with GPIlb (c~m), 
and  not  GPIIIa  (/~3) (D'Souza  et  al.,  1990).  In  contrast, 
there was little binding of laminin and no binding of BSA to 
o~,f13. These results confirm our earlier work (Charo et al., 
1987;  Cheresh,  1987) that  ¢x~/~3 mediated  endothelial  cell 
adherence  to fibrinogen  and vWf, and provide direct evi- 
dence that cx~B3 binds fibronectin and other RGD-contain- 
ing adhesive proteins specifically and with high affinity. 
To determine if the binding of fibronectin to C~v/33 had bi- 
ological  implications  we examined  the  adherence  of two 
related melanoma cell lines to fibronectin.  Although M21 
and M21-L cells express high levels of the fibronectin recep- 
tor  (astir),  it  was  clear  that  the  M21  cells  attached  and 
spread much more readily on fibronectin than did the M21-L 
cells.  This  suggested  that  Otvfl3, which  is  present  on  the 
M21 cells, but not on the M21-L cells, mediated cellular in- 
teractions  with  fibronectin.  Antibody  inhibition  studies 
using LM609 confirmed this hypothesis. We conclude from 
this data that the vitronectin receptor binds fibronectin, and 
that this binding is functionally significant in as much as it 
mediates cellular attachment and spreading on fibronectin. 
Thus, o~,B3 acts in concert with otsBt in promoting M21 cell 
adhesion and spreading on fibronectin. 
The vitronectin receptor appears to be a receptor designed 
to bind the RGD sequence. We have shown that fibronectin, 
fibrinogen,  and  vWf,  in  addition  to  vitronectin,  bind  to 
OtvB3. Lawler  et  al.  (1988)  found  that  ot~B3 binds  throm- 
bospondin. Indeed, it is noteworthy that c~B3 was originally 
purified on an RGD affinity column (Pytela et al.,  1985b), 
which  suggests  that  this  receptor binds  RGD  in  multiple 
adhesive proteins with high affinity. In contrast, the fibronec- 
tin  receptor  (asflt)  interacts  exclusively  with  fibronectin 
(Pytela et al., 1986), and thus appears to recognize the RGD 
sequence only as presented by fibronectin. In a solid-phase 
assay similar  to the one presented  in  this  paper we have 
found that purified otsfl~ binds fibronectin, but does not bind 
fibrinogen, vitronectin,  or vWf (Charo,  I.  F., and L.  Nan- 
nizzi,  unpublished observations). 
Earlier  studies by Pytela et al.  (1985a)  found that o~sflt 
was the predominant cellular receptor in MG-63 osteosar- 
coma cells that bound to the 120-kD fragment of fibronectin 
immobiliTed on Sepharose.  This  study did not report the 
binding of ¢x,fl3 to fibronectin, under conditions very simi- 
lar to those used in this study, nor did it specifically exclude 
this interaction. We used immunoprecipitation with LM609 
to specifically follow the binding and elution of otvB3 from 
the fibronectin column, since the electrophoretic mobility of 
or,t3 and otsfll on SDS gels is very similar.  In addition,  the 
high level of expression of exit3 on M21 cells has facilitated 
the detection of this interaction. 
The relaxed ligand binding: specificity of the vitronectin 
receptor may facilitate the interaction of ~x,fl3 bearing ceils, 
such as malignant melanoma cells, with multiple proteins in 
the extraeellular matrix. It is reasonable to speculate, there- 
fore, that o~,B3 may be important  in metastases of tumors. 
In addition,  SaviU et al.  (1990) have recently reported that 
opsinization of senescent polymorphonuclear leukocytes by 
macrophages occurs via the macrophage o~,f13 receptor.  In- 
terestingly, opsinlzation was inhibited by soluble fibronectin 
as well as by soluble vitronectin.  The interaction between 
fibronectin and otvB3 may thus be of considerable physiolog- 
ical significance. 
The existence of multiple integrins on a given cell capable 
of binding  collagen (Santoro,  1986;  Coller et al.,  1989), 
fibronectin (Wayner et al.,  1989), and vitronectin (Lam et 
al.,  1989) has been described. However, little data exists as 
to the possible biological relevance of this phenomenon.  In 
this report we demonstrate that receptors from two subfami- 
lies  of the  integrin  superfamily,  the  vitronectin  receptor 
avfl3,  and the fibronectin receptor otsB~, can act in concert 
to mediate cell adhesion and spreading on fibronectin. 
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